A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin [folinic acid] (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU.

Trial Profile

A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin [folinic acid] (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2013

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2011 Pooled analysis results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 20 Apr 2009 Results published in Journal of Clinical Oncology 27: Online first [7 pages], 20 Apr 2009.
    • 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top